Table 1.

Demographic data for the schizophrenic and control subjects

Schizophrenia							Control
Patient no.	Sex	Age, y	Tissue pH	PMI, h	DOI	Drug dose, mg*	Patient no.	Sex	Age, y	Tissue pH	PMI, h
1	M	23	6.40	42	6	1750	1	M	23	6.13	36
2	M	38	5.52	40	N/A	160	2	M	30	6.46	24
3	F	27	5.85	41	10	N/A	3	F	21	6.03	58
4	M	55	6.10	25	33	40	4	M	50	6.43	69
5	F	36	6.28	45	4	160	5	F	32	6.16	56
6	M	22	6.29	49	20	2920	6	M	22	6.58	51
7	M	36	6.04	38	12	200	7	M	38	6.42	N/A
8	M	44	6.28	32	23	600	8	M	43	6.25	45
9	M	48	6.62	30	24	1250	9	M	25	6.15	35
10	M	42	6.26	47	22	N/A	10	M	42	6.32	26
11	M	25	6.38	49	2	N/A	11	M	42	6.32	26
12	M	22	6.07	37	3	450	12	M	25	6.48	50
13	F	35	6.26	15	7	300	13	M	26	6.42	24
14	M	41	6.20	31	11	500	14	M	30	5.86	27
15	M	45	6.48	68	12	300	15	M	38	6.19	44
16	M	38	6.02	50	4	500	16	F	33	6.41	42
17	F	31	6.27	27	13	875	17	M	42	6.61	43
18	F	38	6.43	20	17	N/A	18	M	43	6.43	51
19	M	22	6.17	37	3	200	19	F	38	6.26	52
20	M	26	6.39	52	2	500
Mean ± SEM		34.7 ± 2.2	6.21 ± 0.05	38.7 ± 2.9			Mean ± SEM		33.2 ± 2.2	6.32 ± 0.04	41.5 ± 4.5

PMI, post-mortem interval; DOI, duration of illness; N/A, not available. 

^*Drug doses are given as chlorpromazine equivalents.